Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia
Identifieur interne : 004F45 ( Main/Merge ); précédent : 004F44; suivant : 004F46Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia
Auteurs : Inger Marie Skogseid [Norvège] ; Jo R Islien [Norvège] ; Bj Rgulf Claussen [Norvège] ; Emilia Kerty [Norvège]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-12.
English descriptors
- KwdEn :
- Adult, Aged, Anti-Dyskinesia Agents (therapeutic use), Botulinum Toxins (therapeutic use), Chi-Square Distribution, Demography, Employment, Female, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Time Factors, Torticollis (drug therapy), Torticollis (psychology), botulinum toxin type A, cervical dystonia, employment status, long‐term treatment.
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Torticollis.
- psychology : Torticollis.
- Adult, Aged, Chi-Square Distribution, Demography, Employment, Female, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Time Factors.
Abstract
We examined the impact of cervical dystonia (CD) and long‐term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long‐term treatment were obtained from 62 CD patients aged 31–66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5–10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long‐term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20670
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B05
- to stream Istex, to step Curation: 001B05
- to stream Istex, to step Checkpoint: 002268
- to stream PubMed, to step Corpus: 002F00
- to stream PubMed, to step Curation: 002F00
- to stream PubMed, to step Checkpoint: 003073
- to stream Ncbi, to step Merge: 001412
- to stream Ncbi, to step Curation: 001412
- to stream Ncbi, to step Checkpoint: 001412
Links to Exploration step
ISTEX:58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20670</idno><idno type="url">https://api.istex.fr/document/58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B05</idno><idno type="wicri:Area/Istex/Curation">001B05</idno><idno type="wicri:Area/Istex/Checkpoint">002268</idno><idno type="wicri:doubleKey">0885-3185:2005:Skogseid I:long:term:botulinum</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16114026</idno><idno type="wicri:Area/PubMed/Corpus">002F00</idno><idno type="wicri:Area/PubMed/Curation">002F00</idno><idno type="wicri:Area/PubMed/Checkpoint">003073</idno><idno type="wicri:Area/Ncbi/Merge">001412</idno><idno type="wicri:Area/Ncbi/Curation">001412</idno><idno type="wicri:Area/Ncbi/Checkpoint">001412</idno><idno type="wicri:doubleKey">0885-3185:2005:Skogseid I:long:term:botulinum</idno><idno type="wicri:Area/Main/Merge">004F45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo and Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Biostatistics, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Institute of General Practice and Community Medicine, University of Oslo, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo and Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-12">2005-12</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1604">1604</biblScope><biblScope unit="page" to="1609">1609</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD</idno><idno type="DOI">10.1002/mds.20670</idno><idno type="ArticleID">MDS20670</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (therapeutic use)</term><term>Chi-Square Distribution</term><term>Demography</term><term>Employment</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Time Factors</term><term>Torticollis (drug therapy)</term><term>Torticollis (psychology)</term><term>botulinum toxin type A</term><term>cervical dystonia</term><term>employment status</term><term>long‐term treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chi-Square Distribution</term><term>Demography</term><term>Employment</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Time Factors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We examined the impact of cervical dystonia (CD) and long‐term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long‐term treatment were obtained from 62 CD patients aged 31–66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5–10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long‐term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated. © 2005 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20670"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20670</idno><idno type="url">https://api.istex.fr/document/58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B05</idno><idno type="wicri:Area/Istex/Curation">001B05</idno><idno type="wicri:Area/Istex/Checkpoint">002268</idno><idno type="wicri:doubleKey">0885-3185:2005:Skogseid I:long:term:botulinum</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo and Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Biostatistics, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Institute of General Practice and Community Medicine, University of Oslo, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo and Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-12">2005-12</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1604">1604</biblScope><biblScope unit="page" to="1609">1609</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD</idno><idno type="DOI">10.1002/mds.20670</idno><idno type="ArticleID">MDS20670</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>botulinum toxin type A</term><term>cervical dystonia</term><term>employment status</term><term>long‐term treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We examined the impact of cervical dystonia (CD) and long‐term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long‐term treatment were obtained from 62 CD patients aged 31–66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5–10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long‐term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated. © 2005 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name><affiliation wicri:level="1"><nlm:affiliation>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo, Norway. i.m.skogseid@klinmed.uio.no</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20670</idno><idno type="RBID">pubmed:16114026</idno><idno type="pmid">16114026</idno><idno type="wicri:Area/PubMed/Corpus">002F00</idno><idno type="wicri:Area/PubMed/Curation">002F00</idno><idno type="wicri:Area/PubMed/Checkpoint">003073</idno><idno type="wicri:Area/Ncbi/Merge">001412</idno><idno type="wicri:Area/Ncbi/Curation">001412</idno><idno type="wicri:Area/Ncbi/Checkpoint">001412</idno><idno type="wicri:doubleKey">0885-3185:2005:Skogseid I:long:term:botulinum</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia.</title><author><name sortKey="Skogseid, Inger Marie" sort="Skogseid, Inger Marie" uniqKey="Skogseid I" first="Inger Marie" last="Skogseid">Inger Marie Skogseid</name><affiliation wicri:level="1"><nlm:affiliation>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo, Norway. i.m.skogseid@klinmed.uio.no</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>University of Oslo, Department of Neurology, Rikshospitalet University Hospital, Oslo</wicri:regionArea><wicri:noRegion>Oslo</wicri:noRegion></affiliation></author><author><name sortKey="R Islien, Jo" sort="R Islien, Jo" uniqKey="R Islien J" first="Jo" last="R Islien">Jo R Islien</name></author><author><name sortKey="Claussen, Bj Rgulf" sort="Claussen, Bj Rgulf" uniqKey="Claussen B" first="Bj Rgulf" last="Claussen">Bj Rgulf Claussen</name></author><author><name sortKey="Kerty, Emilia" sort="Kerty, Emilia" uniqKey="Kerty E" first="Emilia" last="Kerty">Emilia Kerty</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Botulinum Toxins (therapeutic use)</term><term>Chi-Square Distribution</term><term>Demography</term><term>Employment</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Time Factors</term><term>Torticollis (drug therapy)</term><term>Torticollis (psychology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Torticollis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chi-Square Distribution</term><term>Demography</term><term>Employment</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We examined the impact of cervical dystonia (CD) and long-term botulinum toxin (BTX) treatment on employment status. Data on employment status at onset of CD, at initiation of BTX treatment, and at evaluation of long-term treatment were obtained from 62 CD patients aged 31-66 years (median, 53 years; 61% females) who had been treated for a median of 5 years (range, 1.5-10 years). The employment rate fell from 84% at the onset of CD to 47% before initiation of BTX treatment. With long-term BTX treatment, 72% of those who worked at the initiation of treatment stayed employed, and 67% of those on sick leave returned to work. A younger age and a higher level of education increased the probability of being employed and avoiding disability benefits. Among those who were younger than 55 years at evaluation of BTX treatment (n = 40), the employment rate increased from 47% to 65% with treatment, and among the male patients, it reached the level of the general population (86%). About half of the 34% who received disability benefits did so already before the BTX treatment was initiated.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004F45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:58C4CBCA33ABAFDA88CC60AFFAB283DE154FE3CD
|texte= Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia
}}
| This area was generated with Dilib version V0.6.23. |  |